fluquadri suspension for injection (im)
n/a; importer: sanofi pasteur, inc.; distributor: sanofi pasteur, inc. - quadrivalent seasonal influenza vaccine (split virion, inactivated) 2023 southern hemisphere strain - suspension for injection (im) - formulation: each dose (0.5 ml) contains: a/victoria/2570/2019 ivr-215(hini)-15 mcg* a/darwin/9/2021 san-010 (h3n2)-15 mcg*
vaxigriptetra suspension for injection in pre-filled syringe
sanofi pasteur, france - influenza a virus a/indonesia/5/2005 (h5n1) antigen (uv, formaldehyde inactivated) - suspension for injection in pre-filled syringe - 15 µg,
sanofi caplets tablet blister pack
sanofi-aventis australia pty ltd - codeine phosphate hemihydrate,doxylamine succinate,paracetamol -
dengvaxia md powder and solvent for suspension for injection
sanofi-aventis singapore pte. ltd. - cyd dengue virus serotype 1; cyd dengue virus serotype 2; cyd dengue virus serotype 3; cyd dengue virus serotype 4 - injection, powder, for suspension - cyd dengue virus serotype 1 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 2 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 3 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 4 4.5 - 6.0 log10 ccid50/dose
immucyst
sanofi-aventis singapore pte. ltd. - bacillus calmette-guerin - injection, powder, lyophilized, for solution - 81mg/vial
dengvaxia powder and solvent for suspension for injection
sanofi-aventis singapore pte. ltd. - cyd dengue virus serotype 1; cyd dengue virus serotype 2; cyd dengue virus serotype 3; cyd dengue virus serotype 4 - injection, powder, for suspension - cyd dengue virus serotype 1 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 2 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 3 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 4 4.5 - 6.0 log10 ccid50/dose
menactra
sanofi-aventis australia pty ltd - diphtheria toxoid, quantity: 48 microgram; meningococcal polysaccharide group y, quantity: 4 microgram; meningococcal polysaccharide group w135, quantity: 4 microgram; meningococcal polysaccharide group c, quantity: 4 microgram; meningococcal polysaccharide group a, quantity: 4 microgram - injection, solution - excipient ingredients: monobasic sodium phosphate; sodium chloride; dibasic sodium phosphate - menactra is indicated for active immunisation of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n meningitidis serogroups a, c, y and w-135.,menactra is not indicated for the prevention of meningitis caused by other microorganisms or for the prevention of invasive meningococcal disease caused by n meningitidis serogroup b.,menactra is not indicated for treatment of meningococcal infections.,menactra is not indicated for immunisation against diphtheria.
inactivated influenza vaccine (split virion) bp, suspension for injection in prefilled syringe.influenza vaccine (split virion,
sanofi pasteur - a/michigan/45/2015 (h1n1)pdm09 - like strain (a/michigan/45/2015, nymc x-275); a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b); b/brisbane/60/2008 - like strain (b/brisbane/60/2008) - suspension for injection - 15/15/15mc percent volume/volume - influenza vaccines; influenza, inactivated, split virus or surface antigen
stamaril pasteur nlt 1000 i.u parenteral ordinary vials
sanofi pasteur - yellow fever virus 17d-204 strain(live attenuated) - parenteral ordinary vials - nlt 1000 i.u
risedronate sanofi ec
sanofi-aventis australia pty ltd - risedronate sodium; calcium carbonate; colecalciferol; cholecalciferol -